CCL2 and prostate cancer: As we expected, our study aiming to develop a novel risk classification showed that combining PSA and CCL2 predicted OS, PCaSS, and CFS of all patients with prostate cancer and those treated with ADT compared with PSA or CCL2 alone (Figure 6).